Frost Radar™: Global RNA Delivery Technologies, 2021
Published on: 09-Nov-2021 | SKU: HC03464-GL-TR_25920

Need more details?
$4,950.00
DownloadLink
Need more details?

The year 2018 was a breakthrough period for RNA therapeutics as the first RNA therapy received approval from the FDA. In the wake of the COVID-19 pandemic, RNA vaccines have witnessed immense progress and acceptance globally. These events have contributed massively to growth across the RNA therapeutics market.

Currently, several RNA therapeutics are in different stages of development, including mRNA, tRNA, siRNA, and RNAi therapies, but mostly concentrated in the early pre-clinical and clinical stages. The popularity of RNA therapeutics is demanding the need to establish efficient delivery systems that can overcome current challenges, such as early degradation of RNA therapeutic molecules, toxicity, and non-target specificity.

This RNA Delivery Technologies, 2021 Frost Radar™ covers companies that are developing robust delivery systems for the rapidly growing RNA therapies and adopting the latest advances in nanoscience and chemically modified delivery systems. These delivery systems are critical to achieving the final results in the efficiency of RNA therapeutics.

Frost & Sullivan identifies key companies that are developing innovative RNA delivery technologies and excelling in the field. Although the newer delivery systems are mostly in pre-clinical stages, the potential of newer delivery systems based on exosomes, chemically modified systems, and polymer-based systems are highly promising.

Frost & Sullivan independently plotted the top companies in this Frost Radar™. Our analysis reveals the market positioning of each company using its Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies based on their strengths, opportunities, and market positioning. We discuss strategic market imperatives and the competitive environment that vendors operate in as well as make recommendations for each provider to spur growth.

Strategic Imperative

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Frost Radar™: RNA Delivery Technologies

Frost Radar™

Frost Radar™

Alnylam Pharmaceuticals, US

Arcturus Therapeutics, US

Arrowhead Pharmaceuticals, US

Capricor Therapeutics, US

Codiak Bioscience, US

Dicerna Pharmaceuticals, US

DTx Pharmaceuticals, US

Ethris, Germany

Evox Therapeutics, US

Ionis Pharmaceuticals, US

Precision NanoSystems, Canada

Recode Therapeutics, US

siRNAgen Therapeutics, South Korea

Translate Bio, US

Vesigen Therapeutics, US

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The year 2018 was a breakthrough period for RNA therapeutics as the first RNA therapy received approval from the FDA. In the wake of the COVID-19 pandemic, RNA vaccines have witnessed immense progress and acceptance globally. These events have contributed massively to growth across the RNA therapeutics market. Currently, several RNA therapeutics are in different stages of development, including mRNA, tRNA, siRNA, and RNAi therapies, but mostly concentrated in the early pre-clinical and clinical stages. The popularity of RNA therapeutics is demanding the need to establish efficient delivery systems that can overcome current challenges, such as early degradation of RNA therapeutic molecules, toxicity, and non-target specificity. This RNA Delivery Technologies, 2021 Frost Radar™ covers companies that are developing robust delivery systems for the rapidly growing RNA therapies and adopting the latest advances in nanoscience and chemically modified delivery systems. These delivery systems are critical to achieving the final results in the efficiency of RNA therapeutics. Frost & Sullivan identifies key companies that are developing innovative RNA delivery technologies and excelling in the field. Although the newer delivery systems are mostly in pre-clinical stages, the potential of newer delivery systems based on exosomes, chemically modified systems, and polymer-based systems are highly promising. Frost & Sullivan independently plotted the top companies in this Frost Radar™. Our analysis reveals the market positioning of each company using its Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies based on their strengths, opportunities, and market positioning. We discuss strategic market imperatives and the competitive environment that vendors operate in as well as make recommendations for each provider to spur growth.
More Information
Deliverable Type Frost Radar
No Index No
Podcast No
Author Neeraja Vettekudath
Industries Healthcare
WIP Number DA19-01-00-00-00
Keyword 1 RNA therapeutics
Keyword 2 mRNA
Keyword 3 RNA Delivery Technologies
Is Prebook No

Frost Radar™: Global RNA Delivery Technologies, 2021

HealthcareFrost Radar™: Global RNA Delivery Technologies, 2021

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
09-Nov-2021
REGION
Global
Deliverable Type
Frost Radar
Research Code: DA19-01-00-00-00
SKU: HC03464-GL-TR_25920
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03464-GL-TR_25920